List view / Grid view

Scott Brun

AbbVie submits for EU marketing authorization its investigational, all-oral, interferon-free therapy for the treatment of chronic hepatitis C

AbbVie submitted marketing authorization applications to the European Medicines Agency…

8 May 2014 | By AbbVie

AbbVie submitted marketing authorization applications to the European Medicines Agency seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus infection...

news

Abbvie announces initiation of pivotal Phase III study of veliparib (abt-888) for patients with non-small cell lung cancer

AbbVie announced the initiation of a global Phase III clinical…

15 April 2014 | By AbbVie

AbbVie announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib...

news

Abbvie completes largest phase iii program of an all-oral, interferon-free therapy for the treatment of hepatitis c genotype 1

AbbVie announced the completion of its phase III clinical program…

31 January 2014 | By AbbVie

AbbVie announced the completion of its phase III clinical program and released results of four additional studies designed to assess AbbVie's investigational all-oral, interferon-free therapy...

news

AbbVie releases first of six phase III results from investigational all-oral, interferon-free, 12-week regimen, showing 96% SVR12 in Genotype 1 hepatitis C patients new to therapy

AbbVie's multinational HCV program is the largest all-oral, interferon-free clinical…

18 November 2013 | By AbbVie

AbbVie's multinational HCV program is the largest all-oral, interferon-free clinical program in GT1 patients being conducted to date...

news

Abbott announces Phase 3 hepatitis C program details

Details on its phase 3 hepatitis C registrational program...

13 November 2012 | By Abbott

Details on its phase 3 hepatitis C registrational program...

news

Abbott’s investigational interferon-free Hepatitis C treatment regimen achieved SVR12 (observed data) rates in 99 percent of treatment-naïve

Initial results from "Aviator"...

15 October 2012 | By Abbott

Initial results from "Aviator"...

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Scott Brun

AbbVie submits for EU marketing authorization its investigational, all-oral, interferon-free therapy for the treatment of chronic hepatitis C

Abbvie announces initiation of pivotal Phase III study of veliparib (abt-888) for patients with non-small cell lung cancer

Abbvie completes largest phase iii program of an all-oral, interferon-free therapy for the treatment of hepatitis c genotype 1

AbbVie releases first of six phase III results from investigational all-oral, interferon-free, 12-week regimen, showing 96% SVR12 in Genotype 1 hepatitis C patients new to therapy

Abbott announces Phase 3 hepatitis C program details

Abbott’s investigational interferon-free Hepatitis C treatment regimen achieved SVR12 (observed data) rates in 99 percent of treatment-naïve